Home Cart Sign in  
Chemical Structure| 942398-84-7 Chemical Structure| 942398-84-7

Structure of Amiselimod HCl
CAS No.: 942398-84-7

Chemical Structure| 942398-84-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Amiselimod HCl is a sphingosine 1-phosphate receptor-1 (S1P1) modulator, designed to reduce the bradycardia effects associated with fingolimod and other S1P receptor modulators.

Synonyms: MT-1303 hydrochloride; Amiselimod (hydrochloride); MT-1303

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Amiselimod HCl

CAS No. :942398-84-7
Formula : C19H31ClF3NO3
M.W : 413.90
SMILES Code : OCC(CCC1=CC=C(OCCCCCCC)C(C(F)(F)F)=C1)(N)CO.[H]Cl
Synonyms :
MT-1303 hydrochloride; Amiselimod (hydrochloride); MT-1303
MDL No. :MFCD25372041
InChI Key :GEDVJGOVRLHFQG-UHFFFAOYSA-N
Pubchem ID :67418070

Safety of Amiselimod HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Amiselimod HCl

GPCR

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01666327 Inflammatory Bowel Disease PHASE1 COMPLETED 2025-07-14 Research Site, Nottingham, Uni... More >>ted Kingdom Less <<
NCT02293967 Relapsing-remitting Multiple S... More >>clerosis Less << PHASE1 COMPLETED 2025-12-14 Investigational site, Ruddingt... More >>on, Nottingham, United Kingdom Less <<
NCT02148185 Crohn's Disease PHASE1 COMPLETED 2025-06-14 Inverstigational site, Chubu, ... More >>Japan|Inverstigational site, Kanto, Japan Less <<
NCT02389790 Crohn's Disease PHASE2 COMPLETED 2025-08-17 Investigational site, City Nam... More >>e, Czechia|Investigational site, City Name, France|Investigational site, City Nmae, Germany|Investigational site, City Nmae, Hungary|Investigational site, City Name, Israel|Investigational site, City Name, Italy|Investigational site, City Nmae, Japan|Investigational site, City Name, Netherlands|Investigational site, City Name, Poland|Investigational site, City Name, Slovakia|Investigational site, City Name, Ukraine Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.42mL

0.48mL

0.24mL

12.08mL

2.42mL

1.21mL

24.16mL

4.83mL

2.42mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories